Unseen, Underdiagnosed, Undertreated: Cardiomyopathies Demand Urgent Attention
Cardiomyopathies, a hidden threat to Europe's health, are in dire need of early detection and treatment. This group of heart muscle diseases, often caused by genetic factors, is a leading cause of sudden death and heart transplants, yet it remains largely unnoticed. But here's where it gets controversial: despite its severe impact, cardiomyopathies are underdiagnosed and undertreated, affecting millions of lives.
The Cardiomyopathies Matter initiative, funded by Bristol Myers Squibb and Philips, aims to shed light on this critical issue. Experts argue that early diagnosis, followed by tailored treatment and monitoring, could significantly reduce emergency hospital visits, advanced medical procedures, and long-term disability care. This is a crucial step towards improving cardiovascular health across Europe.
The Silent Killer: Cardiomyopathies in Europe
Cardiovascular diseases (CVDs) are Europe's top health concern, with cardiomyopathies playing a significant role. Annually, CVDs claim 1.8 million lives, accounting for one-third of all deaths, and cost Europe a staggering €282 billion. These diseases not only strain healthcare systems but also lead to lost productivity and long-term care needs.
Recognizing this crisis, the EU is taking action. In December 2024, EU Health Ministers adopted Council Conclusions, emphasizing the need for stronger CVD prevention and early detection. The European Commission also plans to introduce a European Cardiovascular Health Plan, aiming to coordinate strategies for prevention, diagnosis, innovation, and rehabilitation to alleviate the burden of CVDs, including cardiomyopathies.
The Underdiagnosed Threat
Cardiomyopathies weaken the heart's ability to pump blood and are often caused by inherited genetic variants. However, their subtle symptoms, such as fatigue and shortness of breath, make early detection challenging. As a result, many cases are either misdiagnosed or diagnosed too late, leading to severe consequences.
Underdiagnosis has a profound impact on patients' lives, sometimes resulting in fatal outcomes. Early detection, followed by appropriate treatment, can significantly reduce emergency hospitalizations and long-term disability care. Moreover, since many cardiomyopathies are inherited, diagnosing one patient can lead to family screening and risk identification, potentially preventing severe outcomes in relatives.
The Case for Early Diagnosis: A Clinical and Policy Imperative
Early diagnosis of cardiomyopathies is not just a medical goal; it's a policy priority. Detecting these inherited conditions early can improve outcomes for patients, families, and healthcare systems. However, systemic issues in Europe often delay diagnosis until symptoms become irreversible or fatal.
Diagnostic errors are estimated to account for a significant portion of healthcare spending. Reducing these errors could free up substantial funds for other health priorities. For cardiomyopathies, improved diagnosis means preventing unnecessary hospital stays, reducing long-term costs, and saving lives. Early detection allows for less invasive treatments and enables more individuals to lead productive lives.
Challenges and Controversies in Diagnosis
The challenge lies in recognizing cardiomyopathies in their early stages, as symptoms are often overlooked. When diagnosed early, cardiologists can implement targeted therapies, lifestyle changes, and preventive measures to reduce the risk of heart failure and sudden cardiac arrest. This can change the course of the disease and offer hope to countless families.
Healthcare professionals, patient advocates, and policymakers agree that early diagnosis of inherited cardiac diseases should be a fundamental part of EU health policy. However, several barriers must be addressed, including limited awareness among healthcare workers, unequal access to advanced diagnostics, and fragmented regulations around genetic testing.
Cardiac MRI and genetic testing are powerful tools for early diagnosis, but they are underutilized due to a lack of standardized screening policies and specialist training. Additionally, the human impact of delayed diagnosis extends beyond physical health, affecting mental well-being, family relationships, and life opportunities. Integrating psychological support and peer networks into care is essential for a comprehensive, patient-centered approach.
A Call to Action: Saving Lives Through Early Diagnosis
As the European Union shapes its future health agenda, it's crucial to prioritize early diagnosis of cardiomyopathies. Cardiomyopathies Matter advocates for embedding early diagnosis into the core of EU health systems to ensure no patient suffers due to late detection. This approach is vital for reducing preventable deaths, enhancing quality of life, and optimizing healthcare spending.
Healthcare professionals, researchers, and patient representatives urge European policymakers to take decisive action. Addressing the gaps in early diagnosis of CVDs, including cardiomyopathies, is essential. By implementing the 2024-2029 policy recommendations, the EU can make significant strides in tackling this hidden health crisis.
Policy Recommendations for a Healthier Europe
- Integrate early detection of cardiomyopathies into the EU's broader preventive health and non-communicable disease agenda.
- Support Member States in implementing a European Cardiovascular Health Check, including early cardiomyopathy detection and improved access to advanced diagnostic tools.
- Promote systematic screening of family members of patients with inherited cardiomyopathies, along with genetic counseling and testing, and establish legal frameworks to facilitate genetic information sharing.
- Raise awareness of early cardiomyopathy symptoms among patients and healthcare providers, and enhance training for cardiologists and radiologists to improve advanced imaging interpretation.
By embracing these recommendations, the EU and its Member States can effectively address the health, social, and economic challenges posed by cardiomyopathies, ensuring a healthier future for all Europeans.
About the Authors:
Patricia Tiramani, Rogier Veltrop, and Tootie Bueser are experts in the field of cardiomyopathies and healthcare policy, representing various organizations and institutions. Their collective expertise contributes to the Cardiomyopathies Matter initiative, aiming to raise awareness and improve policies related to cardiomyopathies.
Learn More:
- Cardiomyopathies Matter Policy Roadmap
- Cardiomyopathies Matter Policy Recommendations for 2024-2029
- Cardiomyopathies Matter Policy Debate on Early Diagnosis
References:
1. Luengo-Fernandez et al., Economic burden of cardiovascular diseases in the European Union, European Heart Journal, 2023.
2. Council of the European Union, Conclusions on cardiovascular health, 2024.
3. Europe's Choice, Political Guidelines for the next European Commission, 2024.
4. Cardiomyopathies Matter, Policy Roadmap, 2022.
5. Lannou et al., Cardiomyopathies' public health burden, J Clin Med, 2020.
6. Slawomirski et al., Diagnostic safety economics, OECD Health Working Papers, 2025.
7. Cardiomyopathies Matter, EU cardiovascular disease policies, Policy Recommendations, 2024.
Stay Informed:
Subscribe to The Parliament's newsletter for weekly insights on EU affairs.
